145 related articles for article (PubMed ID: 24586361)
1. Deficient phosphorylation of Stat1 in leukocytes identifies neutralizing antibodies in multiple sclerosis patients treated with interferon-beta.
Gavasso S; Mosleth EF; Marøy T; Jørgensen K; Nakkestad HL; Gjertsen BT; Myhr KM; Vedeler C
PLoS One; 2014; 9(2):e88632. PubMed ID: 24586361
[TBL] [Abstract][Full Text] [Related]
2. Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis.
Gavasso S; Gjertsen B; Anderssen E; Myhr K; Vedeler C
Mult Scler; 2012 Aug; 18(8):1116-24. PubMed ID: 22287540
[TBL] [Abstract][Full Text] [Related]
3. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity.
Hesse D; Sellebjerg F; Sorensen PS
Neurology; 2009 Aug; 73(5):372-7. PubMed ID: 19652141
[TBL] [Abstract][Full Text] [Related]
4. Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.
Hegen H; Millonig A; Bertolotto A; Comabella M; Giovanonni G; Guger M; Hoelzl M; Khalil M; Killestein J; Lindberg R; Malucchi S; Mehling M; Montalban X; Polman CH; Rudzki D; Schautzer F; Sellebjerg F; Sørensen PS; Deisenhammer F
Mult Scler; 2014 Apr; 20(5):577-87. PubMed ID: 24009164
[TBL] [Abstract][Full Text] [Related]
5. Human leukocyte antigen genes and interferon beta preparations influence risk of developing neutralizing anti-drug antibodies in multiple sclerosis.
Link J; Lundkvist Ryner M; Fink K; Hermanrud C; Lima I; Brynedal B; Kockum I; Hillert J; Fogdell-Hahn A
PLoS One; 2014; 9(3):e90479. PubMed ID: 24608124
[TBL] [Abstract][Full Text] [Related]
6. Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice.
Farrell RA; Espasandin M; Lakdawala N; Creeke PI; Worthington V; Giovannoni G
Mult Scler; 2011 Nov; 17(11):1333-40. PubMed ID: 21685230
[TBL] [Abstract][Full Text] [Related]
7. Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1.
Feng X; Petraglia AL; Chen M; Byskosh PV; Boos MD; Reder AT
J Neuroimmunol; 2002 Aug; 129(1-2):205-15. PubMed ID: 12161037
[TBL] [Abstract][Full Text] [Related]
8. Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferon-β.
Hesse D; Frederiksen JL; Koch-Henriksen N; Schreiber K; Stenager E; Heltberg A; Ravnborg M; Bendtzen K; Sellebjerg F; Sorensen PS
Eur J Neurol; 2009 Jan; 16(1):43-7. PubMed ID: 19087149
[TBL] [Abstract][Full Text] [Related]
9. Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies.
Santos R; Weinstock-Guttman B; Tamaño-Blanco M; Badgett D; Zivadinov R; Justinger T; Munschauer F; Ramanathan M
J Neuroimmunol; 2006 Jul; 176(1-2):125-33. PubMed ID: 16698090
[TBL] [Abstract][Full Text] [Related]
10. Persistency of neutralizing antibodies depends on titer and interferon-beta preparation.
Hegen H; Schleiser M; Gneiss C; Di Pauli F; Ehling R; Kuenz B; Lutterotti A; Berger T; Deisenhammer F
Mult Scler; 2012 May; 18(5):610-5. PubMed ID: 22013146
[TBL] [Abstract][Full Text] [Related]
11. Use of a standardized MxA protein measurement-based assay for validation of assays for the assessment of neutralizing antibodies against interferon-β.
Wadhwa M; Subramanyam M; Goelz S; Goyal J; Jethwa V; Jones W; Files JG; Kramer D; Bird C; Dilger P; Tovey M; Lallemand C; Thorpe R
J Interferon Cytokine Res; 2013 Nov; 33(11):660-71. PubMed ID: 23848523
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies.
Scagnolari C; Duda P; Bagnato F; De Vito G; Alberelli A; Lavolpe V; Girardi E; Durastanti V; Trojano M; Kappos L; Antonelli G
J Neurol; 2007 May; 254(5):597-604. PubMed ID: 17420930
[TBL] [Abstract][Full Text] [Related]
13. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP
J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
[TBL] [Abstract][Full Text] [Related]
14. Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies?
Sorensen PS; Koch-Henriksen N; Flachs EM; Bendtzen K
Mult Scler; 2008 Jul; 14(6):837-42. PubMed ID: 18505772
[TBL] [Abstract][Full Text] [Related]
15. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S;
Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883
[TBL] [Abstract][Full Text] [Related]
16. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy.
Sorensen PS; Koch-Henriksen N; Ross C; Clemmesen KM; Bendtzen K;
Neurology; 2005 Jul; 65(1):33-9. PubMed ID: 15888603
[TBL] [Abstract][Full Text] [Related]
17. Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients.
Vallittu AM; Halminen M; Peltoniemi J; Ilonen J; Julkunen I; Salmi A; Erälinna JP;
Neurology; 2002 Jun; 58(12):1786-90. PubMed ID: 12084878
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice.
Jungedal R; Lundkvist M; Engdahl E; Ramanujam R; Westerlind H; Sominanda A; Hillert J; Fogdell-Hahn A
Mult Scler; 2012 Dec; 18(12):1775-81. PubMed ID: 22551640
[TBL] [Abstract][Full Text] [Related]
19. Cross-reactivity of antibodies against interferon beta in multiple sclerosis patients and interference of the JAK-STAT signaling pathway.
Hurtado-Guerrero I; Pinto-Medel MJ; Urbaneja P; Rodriguez-Bada JL; Ortega-Pinazo J; Serrano P; Fernández Ó; Leyva L; Oliver-Martos B
Sci Rep; 2017 Nov; 7(1):16585. PubMed ID: 29185487
[TBL] [Abstract][Full Text] [Related]
20. Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assay.
Massart C; Gibassier J; de Seze J; Debouverie M; Moreau T; Pelletier J; Vermersch P; Edan G
Clin Chim Acta; 2008 May; 391(1-2):98-101. PubMed ID: 18249193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]